Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. CT Texture Analysis for Predicting Prognosis of Patients With Metastatic RCC Treated With Immune Checkpoint Inhibitors
  2. Genomic and Metabolic Variation in SDH- and FH-deficient RCC
  3. Safety and Oncologic Outcomes of Cryoablation of RCC in the Ipsilateral Kidney Following Partial Nephrectomy
  4. Cabozantinib Plus Nivolumab in Patients With Non–Clear Cell RCC and Genomic Correlates
  5. Efficacy of ICI Rechallenge With Nivolumab or Nivolumab–Ipilimumab Combination in mRCC
  6. Association of Sarcopenia and Systemic Inflammation With Survival After Cytoreductive Nephrectomy for mRCC
  7. Comparison of First-Line Anti–PD-1-Based Combination Therapies in mRCC
  8. Prospective Cardiovascular Surveillance With ICI-Based Combination Treatment in Patients With Advanced RCC
  9. Nivolumab Plus Ipilimumab With or Without Live Bacterial Supplementation in mRCC
  10. Predicting Response to ICI Therapy Using ctDNA in Metastatic Renal Cell Carcinoma

Elsewhere

Recently Updated